Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 11/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.56 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.56 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.56 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.56 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.56 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.56 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.56 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.56 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1373512 | 0.89 | APP (1.00) | APPCYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL1374640 | 0.89 | APP (0.79) | APPCYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL1374496 | 0.87 | APP (1.00) | APPCYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL3942347 | 0.85 | APP (0.92) | APPCYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL3936259 | 0.84 | APP (0.90) | APPCYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL4990072 | 0.84 | APP (0.89) | APPCYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL1373499 | 0.84 | APP (1.00) | APPCYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL1375291 | 0.82 | CYP3A4 (1.00) | APPCYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL1375280 | 0.82 | CYP3A4 (1.00) | APPCYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL1372746 | 0.81 | CYP3A4 (0.98) | APPCYP2C9CYP3A4CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046119-A2 | TREATMENT OF PSYCHIATRIC DISORDERS | Myriad Genetics, Inc. (US) | 2009-04-15 | — | — | EP | claimed |
| WO-2008036733-A2 | METHODS FOR TREATMENT OF VESICLE TRANSPORT DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| US-20080033045-A1 | TREATMENT OF PSYCHIATRIC DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-07 | — | — | US | claimed |
| WO-2008006099-A2 | TREATMENT OF PSYCHIATRIC DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-01-10 | — | — | WO | claimed |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070232672-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-05 | — | — | US | claimed |
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MYRIAD GENETICS, INCORPORATED (US) | 2007-01-18 | — | — | US | claimed |
| WO-2006020850-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| WO-2006020852-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| WO-2006020853-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-9592210-B2 | 1-phenylalkanecarboxylic acid derivatives for the treatment of cognitive impairment | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-03-14 | — | — | US | disclosed |
| WO-2015173133-A1 | FORMULATIONS AND METHODS OF TREATING ALZHEIMER'S DISEASE AND OTHER PROTEINOPATHIES BY COMBINATION THERAPY | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-11-19 | — | — | WO | disclosed |
| US-20150320706-A1 | FORMULATIONS AND METHODS OF TREATING ALZHEIMER'S DISEASE AND OTHER PROTEINOPATHIES BY COMBINATION THERAPY | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-11-12 | — | — | US | disclosed |
| US-20150065567-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND MULTIPLE SCLEROSIS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-05 | — | — | US | disclosed |
| WO-2006001877-A2 | COMBINATION TREATMENT FOR NEURODEGENERATIVE DISORDERS COMPRISING R-FLURBIPROFEN | MYRIAD GENETICS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288375-A1 | Method and composition for treating neurodegenerative disorders | MYRIAD GENETICS, INCORPORATED (US) | 2005-12-29 | — | — | US | disclosed |
| EP-1594833-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CHIESI FARMACEUTICI S.p.A. (IT) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004074232-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CHIESI FARMACEUTICI S.P.A. (IT) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MME, AVPR1B, AVPR2 | APP 2522/4885CYP2C9 3765/4885CYP3A4 3614/4885 |
| US-20070232672-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | APP 21/4885CYP2C9 1035/4885CYP3A4 705/4885 |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | APP 29/4885CYP2C9 1156/4885CYP3A4 745/4885 |
| US-20150320706-A1 | FORMULATIONS AND METHODS OF TREATING ALZHEIMER'S DISEASE AND OTHER PROTEINOPATHIES BY COMBINATION THERAPY | MAPT, GABRA5, MAP1LC3A | APP 6/4885CYP2C9 4477/4885CYP3A4 4275/4885 |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | PSEN2, APP, PSEN1 | APP 2/4885CYP2C9 4757/4885CYP3A4 4028/4885 |
| US-20150065567-A1 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND MULTIPLE SCLEROSIS | PSEN1, APP, PSEN2 | APP 2/4885CYP2C9 3448/4885CYP3A4 3081/4885 |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | APP 21/4885CYP2C9 1035/4885CYP3A4 705/4885 |
| US-20080033045-A1 | TREATMENT OF PSYCHIATRIC DISORDERS | SLC6A3, SLC6A2, FKBP5 | APP 2500/4885CYP2C9 2722/4885CYP3A4 1942/4885 |
| US-20050288375-A1 | Method and composition for treating neurodegenerative disorders | GRIN2A, GRIN2B, GRIN3A | APP 8/4885CYP2C9 56/4885CYP3A4 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.